Cytokinetics Incorporated (CYTK)
CYTK trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$61.62
-1.86% on the day
Market cap
$8.6B
Mid cap
Revenue · 2025
$88.0M
+376.6% on 2024
Net income · 2025
-$785.0M
-891.6% net margin
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.
Profile
| Field | Value |
|---|---|
| Ticker | CYTK on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2004 |
| SEC CIK | 0001061983 |
| SEC industry code | Pharmaceutical Preparations |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $88.0M |
| Net income | -$785.0M |
| Operating income | -$612.3M |
| Net margin | -891.6% |
| Operating margin | -695.4% |
| Revenue growth | +376.6% |
| Cash | $122.5M |
| Total assets | $1.4B |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 97.3× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-05-07 |
| Latest annual report | 10-K | 2026-02-26 |
| Latest quarterly / interim | 10-Q | 2026-08-06 |
| Latest current report | 8-K | 2026-08-28 |
| Latest proxy | DEF 14A | 2026-04-17 |
Source: SEC EDGAR submissions feed, 1,000 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +3.5% |
| 1 month | -8.8% |
| 3 months | -21.3% |
| Year to date | -0.5% |
| 1 year | +6.1% |
| From 52-week high | -27.5% |
Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| TGTX | TG Therapeutics Inc. | $54.34 | -1.68% | $8.3B |
| ARWR | Arrowhead Pharmaceuticals Inc. | $58.13 | -4.28% | $8.2B |
| PTGX | Protagonist Therapeutics Inc. | $138.49 | -4.41% | $9.0B |
| AXSM | Axsome Therapeutics Inc. | $156.32 | -5.83% | $8.2B |
| ABVX | Abivax SA | $86.22 | -0.83% | $7.5B |
| SYRE | Spyre Therapeutics Inc. | $80.45 | -6.34% | $7.1B |
| IONS | Ionis Pharmaceuticals Inc. | $42.38 | -2.95% | $7.0B |
| MDGL | Madrigal Pharmaceuticals Inc. | $452.12 | -3.22% | $10.4B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier